All In Biotech

Drug Trial Radar · NCT01258673

A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy

A Randomized, Double-blind, Multicenter Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy in Comparison With Fimasartan Monotherapy for Essential Hypertension Patients Not Controlled by Fimasartan 60mg(Phase 3)

Last checked: Nov 19, 2026Latest source record: Jan 5, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 263 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

263

Actual

Start

Nov 2010

Primary completion

Dec 2011

Sponsor

Sponsor type
Industry
Collaborators
Seoul National University Hospital; The Catholic University of Korea; Korea University Guro Hospital; DongGuk University; Seoul National University Bundang Hospital; Samsung Medical Center; Asan Medical Center; Gangnam Severance Hospital; Severance Hospital; Ajou University; Chonbuk National University Hospital; Cheil General Hospital and Women's Healthcare Center; Chonnam National University Hospital; Hanyang University Guri Hospital; Yonsei University; Ilsan-Paik Hospital; SMG-SNU Boramae Medical Center; Kyung Hee University Hospital
First posted
Dec 13, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan/Hydrochlorothiazide combination 60/12.5mg\~120/12.5mg in patients with essential hypertension who are not controlled by fimasartan 60mg.

Conditions

  • Essential Hypertension

Interventions

  • Fimasartan/HCTZ combinationDrug

    Fimasartan/HCTZ combination 60/12.5mg 120/12.5mg

  • FimasartanDrug

    Fimasartan 60mg, 120mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Diastolic Blood PressureTime frame: 4week

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Hospital, Bundang

    Sungnam, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.